Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed newly diagnosed glioblastoma multiforme~* Has undergone prior gross total resection (GTR) followed by conformal radiotherapy\* with or without concurrent chemotherapy~  * GTR is defined as ≥ 95% volumetric resection of the contrast-enhancing component on the preoperative MRI~ * Residual radiographic contrast enhancement on post-resection CT scan or MRI must be ≤ 1 cm in maximal diameter in any two perpendicular axial planes~ * No evidence of disease progression after completion of radiotherapy\* NOTE: \*Patients may enroll in part 2 of the study within 2 weeks after surgery; these patients will receive radiotherapy with concurrent chemotherapy during the study~* EGFRvIII-positive tumor by immunohistochemistry, polymerase chain reaction, or related molecular techniques~* Karnofsky performance status 80-100%~* Curran group status I-IV~* Signed informed consent form~Exclusion Criteria:~* Absolute Neutrophil Count (ANC) \< 1,000/mm³~* Platelet count \< 50,000/mm³~* Prothrombin Time/Partial Thromboplastin Time (PT/PTT) \> 1.5 times normal~* Positive hepatitis B (HB) surface antigen (HbsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc)~* Pregnant or nursing~* Positive pregnancy test~* Active infection requiring treatment~* Unexplained febrile illness (T max \> 101.5 F)~* Inflammatory bowel disease, lupus erythematosus, rheumatoid arthritis, or other autoimmune disease~* Known immunosuppressive disease~* Known HIV infection~* Diffuse leptomeningeal disease~* Unstable or severe concurrent medical condition, such as severe heart and lung disease or active hepatitis~* Demonstrated allergy to temozolomide or inability to tolerate temozolomide for reasons other than lymphopenia~* Concurrent corticosteroids (except for nasal or inhaled steroids) at a dose above physiologic levels (\> 2 mg of dexamethasone/day).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (ACTIVATE) (Type: EXPERIMENTAL): Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
- Arm II (ACT II STD) (Type: EXPERIMENTAL): Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
- Arm III (ACT II DI) (Type: EXPERIMENTAL): Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).